{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:21:57Z","timestamp":1790716917286,"version":"4.1.0"},"reference-count":86,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK115454"],"award-info":[{"award-number":["R01DK115454"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["R01GM142143"],"award-info":[{"award-number":["R01GM142143"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RR140038"],"award-info":[{"award-number":["RR140038"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["T32DK060445"],"award-info":[{"award-number":["T32DK060445"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"HHS | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","award":["T32HL092332"],"award-info":[{"award-number":["T32HL092332"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HHS | NIH | National Institute on Aging","award":["R01AG047924"],"award-info":[{"award-number":["R01AG047924"]}]},{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK127037"],"award-info":[{"award-number":["R01DK127037"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["P30DK56338"],"award-info":[{"award-number":["P30DK56338"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HHS | NIH | National Cancer Institute","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}]},{"name":"HHS | NIH | Office of Research Infrastructure Programs, National Institutes of Health","award":["S10OD02346901"],"award-info":[{"award-number":["S10OD02346901"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}]},{"name":"HHS | NIH | National Center for Research Resources","award":["S10RR024574"],"award-info":[{"award-number":["S10RR024574"]}]},{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["P30DK56338"],"award-info":[{"award-number":["P30DK56338"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000066","name":"HHS | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"crossref","award":["P30ES030285"],"award-info":[{"award-number":["P30ES030285"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP180672"],"award-info":[{"award-number":["RP180672"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP150578"],"award-info":[{"award-number":["RP150578"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP170719"],"award-info":[{"award-number":["RP170719"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:p>Proteasome inhibitors have become the standard of care for multiple myeloma. Blocking protein degradation particularly perturbs the homeostasis of short-lived polypeptides such as transcription factors and epigenetic regulators. To determine how proteasome inhibitors directly impact gene regulation, we performed an integrative genomics study in multiple myeloma cells. We discovered that proteasome inhibitors reduce the turnover of DNA-associated proteins and repress genes necessary for proliferation through epigenetic silencing. Specifically, proteasome inhibition results in the localized accumulation of histone deacetylase 3 (HDAC3) at defined genomic sites, which reduces H3K27 acetylation and increases chromatin condensation. The loss of active chromatin at super-enhancers critical for multiple myeloma, including the super-enhancer controlling the proto-oncogene c-MYC, reduces metabolic activity and cancer cell growth. Epigenetic silencing is attenuated by HDAC3 depletion, suggesting a tumor-suppressive element of this deacetylase in the context of proteasome inhibition. In the absence of treatment, HDAC3 is continuously removed from DNA by the ubiquitin ligase Seven in Absentia Homolog 2 (SIAH2). Overexpression of SIAH2 increases H3K27 acetylation at c-MYC\u2013controlled genes, increases metabolic output, and accelerates cancer cell proliferation. Our studies indicate a novel therapeutic function of proteasome inhibitors in multiple myeloma by reshaping the epigenetic landscape in an HDAC3-dependent manner. As a result, blocking the proteasome effectively antagonizes c-MYC and the genes controlled by this proto-oncogene.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Integrative genomics reveals that a key function of proteasome inhibitors involves limiting the activity of MYC and MYC-dependent genes through epigenetic repression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0255","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T11:28:46Z","timestamp":1670498926000},"page":"1693-1710","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-5395","authenticated-orcid":true,"given":"Laure","family":"Maneix","sequence":"first","affiliation":[{"name":"1Huffington Center on Aging, Baylor College of Medicine, Houston, Texas."},{"name":"2Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."},{"name":"4Cell and Gene Therapy Program at the Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-7252","authenticated-orcid":true,"given":"Polina","family":"Iakova","sequence":"additional","affiliation":[{"name":"1Huffington Center on Aging, Baylor College of Medicine, Houston, Texas."},{"name":"2Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."},{"name":"4Cell and Gene Therapy Program at the Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9479-6385","authenticated-orcid":true,"given":"Shannon E.","family":"Moree","sequence":"additional","affiliation":[{"name":"1Huffington Center on Aging, Baylor College of Medicine, Houston, Texas."},{"name":"2Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."},{"name":"4Cell and Gene Therapy Program at the Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-0650","authenticated-orcid":true,"given":"Joanne I.","family":"Hsu","sequence":"additional","affiliation":[{"name":"2Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."},{"name":"4Cell and Gene Therapy Program at the Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7185-9424","authenticated-orcid":true,"given":"Ragini M.","family":"Mistry","sequence":"additional","affiliation":[{"name":"5Integrated Microscopy Core and GCC Center for Advanced Microscopy and Image Informatics, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6029-5478","authenticated-orcid":true,"given":"Fabio","family":"Stossi","sequence":"additional","affiliation":[{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."},{"name":"5Integrated Microscopy Core and GCC Center for Advanced Microscopy and Image Informatics, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-2331","authenticated-orcid":true,"given":"Premal","family":"Lulla","sequence":"additional","affiliation":[{"name":"4Cell and Gene Therapy Program at the Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"6Department of Hematology-Oncology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-0633","authenticated-orcid":true,"given":"Zheng","family":"Sun","sequence":"additional","affiliation":[{"name":"1Huffington Center on Aging, Baylor College of Medicine, Houston, Texas."},{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-2737","authenticated-orcid":true,"given":"Ergun","family":"Sahin","sequence":"additional","affiliation":[{"name":"1Huffington Center on Aging, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-8949","authenticated-orcid":true,"given":"Sarvari V.","family":"Yellapragada","sequence":"additional","affiliation":[{"name":"6Department of Hematology-Oncology, Baylor College of Medicine, Houston, Texas."},{"name":"7Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3572-7598","authenticated-orcid":true,"given":"Andr\u00e9","family":"Catic","sequence":"additional","affiliation":[{"name":"1Huffington Center on Aging, Baylor College of Medicine, Houston, Texas."},{"name":"2Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."},{"name":"4Cell and Gene Therapy Program at the Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"7Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CMAR.S105163","article-title":"Update on the optimal use of bortezomib in the treatment of multiple myeloma","volume":"9","author":"Mohan","year":"2017","journal-title":"Cancer Manag Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/cr.2016.35","article-title":"E2 enzymes: more than just middle men","volume":"26","author":"Stewart","year":"2016","journal-title":"Cell Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molcel.2009.01.014","article-title":"Nonproteolytic functions of ubiquitin in cell signaling","volume":"33","author":"Chen","year":"2009","journal-title":"Mol Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin Oncol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","article-title":"Global quantification of mammalian gene expression control","volume":"473","author":"Schwanhausser","year":"2011","journal-title":"Nature"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-386469-7.00004-9","article-title":"Proteolytic control of the oncoprotein transcription factor Myc","volume":"110","author":"Thomas","year":"2011","journal-title":"Adv Cancer Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2009.09.005","article-title":"Transcription dynamics","volume":"35","author":"Hager","year":"2009","journal-title":"Mol Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-biochem-052110-120012","article-title":"Ubiquitin and proteasomes in transcription","volume":"81","author":"Geng","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1073\/pnas.1200854109","article-title":"Similar temporal and spatial recruitment of native 19S and 20S proteasome subunits to transcriptionally active chromatin","volume":"109","author":"Geng","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ncb1601","article-title":"The ubiquitin-specific protease USP28 is required for MYC stability","volume":"9","author":"Popov","year":"2007","journal-title":"Nat Cell Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.11.016","article-title":"Genome-wide map of nuclear protein degradation shows NCoR1 turnover as a key to mitochondrial gene regulation","volume":"155","author":"Catic","year":"2013","journal-title":"Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1073\/pnas.1019736108","article-title":"The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo","volume":"108","author":"Meerbrey","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.7732382","article-title":"Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin","volume":"268","author":"Fenteany","year":"1995","journal-title":"Science"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"13942","DOI":"10.1038\/s41598-020-70610-0","article-title":"The ubiquitin ligase Cullin-1 associates with chromatin and regulates transcription of specific c-MYC target genes","volume":"10","author":"Sweeney","year":"2020","journal-title":"Sci Rep"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nbt.2450","article-title":"Differential analysis of gene regulation at transcript resolution with RNA-seq","volume":"31","author":"Trapnell","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"e21856","DOI":"10.7554\/eLife.21856","article-title":"An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites","volume":"6","author":"Skene","year":"2017","journal-title":"Elife"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat Protoc"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/cancers13040843","article-title":"The mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma","volume":"13","author":"Maneix","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.1665","article-title":"The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models","volume":"28","author":"Shi","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ng1966","article-title":"Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome","volume":"39","author":"Heintzman","year":"2007","journal-title":"Nat Genet"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.tibs.2017.10.004","article-title":"Histone marks in the 'Driver's Seat': functional roles in steering the transcription cycle","volume":"42","author":"Gates","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.molcel.2013.01.038","article-title":"Modification of enhancer chromatin: what, how, and why?","volume":"49","author":"Calo","year":"2013","journal-title":"Mol Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells","volume":"78","author":"van Nieuwenhuijzen","year":"2018","journal-title":"Cancer Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jncimonographs\/lgn011","article-title":"Characterization of MYC translocations in multiple myeloma cell lines","author":"Dib","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1073\/pnas.0909344107","article-title":"Histone modification levels are predictive for gene expression","volume":"107","author":"Karli\u0107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"604143","DOI":"10.3389\/fonc.2020.604143","article-title":"Mitochondrial bioenergetics at the onset of drug resistance in hematological malignancies: an overview","volume":"10","author":"Barbato","year":"2020","journal-title":"Front Oncol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41580-018-0076-0","article-title":"Integrative regulation of physiology by histone deacetylase 3","volume":"20","author":"Emmett","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","article-title":"MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations","volume":"49","author":"Rath","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrm1049","article-title":"How the ubiquitin-proteasome system controls transcription","volume":"4","author":"Muratani","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/cancers14030806","article-title":"Imaging-based screening of deubiquitinating proteases identifies otubain-1 as a stabilizer of c-MYC","volume":"14","author":"Moree","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2010.07.127","article-title":"The Ski protein negatively regulates Siah2-mediated HDAC3 degradation","volume":"399","author":"Zhao","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"562","DOI":"10.14348\/molcells.2015.0051","article-title":"miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3","volume":"38","author":"Kim","year":"2015","journal-title":"Mol Cells"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41419-018-0462-8","article-title":"PIWIL2 suppresses Siah2-mediated degradation of HDAC3 and facilitates CK2\u03b1-mediated HDAC3 phosphorylation","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ccr.2013.02.016","article-title":"The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity","volume":"23","author":"Qi","year":"2013","journal-title":"Cancer Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2016.01.013","article-title":"The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia","volume":"42","author":"Chen","year":"2016","journal-title":"Leuk Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2010.05.024","article-title":"Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors","volume":"18","author":"Qi","year":"2010","journal-title":"Cancer Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1158\/0008-5472.CAN-11-3310","article-title":"Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy","volume":"72","author":"Wong","year":"2012","journal-title":"Cancer Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41467-019-13826-7","article-title":"Siah2 control of T-regulatory cells limits anti-tumor immunity","volume":"11","author":"Scortegagna","year":"2020","journal-title":"Nat Commun"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"27333","DOI":"10.1074\/jbc.M111.218214","article-title":"USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains","volume":"286","author":"Scortegagna","year":"2011","journal-title":"J Biol Chem"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1093\/emboj\/cdf576","article-title":"Stress-induced decrease in TRAF2 stability is mediated by Siah2","volume":"21","author":"Habelhah","year":"2002","journal-title":"EMBO J"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41419-020-03351-7","article-title":"Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells","volume":"12","author":"Slomp","year":"2021","journal-title":"Cell Death Dis"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.18632\/oncotarget.4620","article-title":"Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression","volume":"6","author":"Suk","year":"2015","journal-title":"Oncotarget"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3390\/cancers13071662","article-title":"Myc-related mitochondrial activity as a novel target for multiple myeloma","volume":"13","author":"Ortiz-Ruiz","year":"2021","journal-title":"Cancers"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-15-2477","article-title":"Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma","volume":"76","author":"Ravi","year":"2016","journal-title":"Cancer Res"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovi\u0107","year":"2018","journal-title":"Leukemia"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3324\/haematol.2019.217927","article-title":"Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma","volume":"105","author":"Mikulasova","year":"2020","journal-title":"Haematologica"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/MCB.20.7.2423-2435.2000","article-title":"c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells","volume":"20","author":"Gregory","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1128\/MCB.18.10.5961","article-title":"myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome","volume":"18","author":"Flinn","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.molcel.2015.11.007","article-title":"Ubiquitin-dependent turnover of MYC antagonizes MYC\/PAF1C complex accumulation to drive transcriptional elongation","volume":"61","author":"Jaenicke","year":"2016","journal-title":"Mol Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/ejh.13405","article-title":"c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma","volume":"105","author":"Di Bacco","year":"2020","journal-title":"Eur J Haematol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br J Cancer"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","article-title":"An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrg2736","article-title":"Deconstructing repression: evolving models of co-repressor action","volume":"11","author":"Perissi","year":"2010","journal-title":"Nat Rev Genet"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/s41467-019-11046-7","article-title":"Chemical genomics reveals histone deacetylases are required for core regulatory transcription","volume":"10","author":"Gryder","year":"2019","journal-title":"Nat Commun"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"e0143376","DOI":"10.1371\/journal.pone.0143376","article-title":"The expression of the ubiquitin ligase SIAH2 (Seven In Absentia Homolog 2) is increased in human lung cancer","volume":"10","author":"Moreno","year":"2015","journal-title":"PLoS One"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1128\/MCB.25.23.10220-10234.2005","article-title":"Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription","volume":"25","author":"Faiola","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/leu.2017.144","article-title":"HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications","volume":"31","author":"Harada","year":"2017","journal-title":"Leukemia"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","article-title":"Recent progress in histone deacetylase inhibitors as anticancer agents","volume":"27","author":"Cappellacci","year":"2020","journal-title":"Curr Med Chem"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2013.231","article-title":"Histone deacetylase 3 as a novel therapeutic target in multiple myeloma","volume":"28","author":"Minami","year":"2014","journal-title":"Leukemia"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41375-019-0493-x","article-title":"Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41586-020-2576-2","article-title":"Dichotomous engagement of HDAC3 activity governs inflammatory responses","volume":"584","author":"Nguyen","year":"2020","journal-title":"Nature"},{"key":"2023032314130917800_","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0255\/3230019\/crc-22-0255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1693\/3285335\/crc-22-0255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1693\/3285335\/crc-22-0255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T12:55:43Z","timestamp":1701521743000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/12\/1693\/711986\/Proteasome-Inhibitors-Silence-Oncogenes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0255","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6551216.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546577.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546583","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546642.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546592","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546580","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546580.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546586.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546583.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546589","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546589.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546577","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546586","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546595","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546595.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551216","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}